Cargando…

High mutation load, immune-activated microenvironment, favorable outcome, and better immunotherapeutic efficacy in melanoma patients harboring MUC16/CA125 mutations

Immunotherapies have dramatically improved survival outcome for patients with melanoma. MUC16 encodes cancer antigen 125 (CA125), which is frequently mutated in melanoma. In this study, we correlated the MUC16 mutational status with the following: tumor mutation burden (TML), multiple immune-related...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Qinghua, Yang, Yichen, Yang, Meng, Li, Xiangchun, Chen, Kexin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals 2020
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7346065/ https://www.ncbi.nlm.nih.gov/pubmed/32491995 http://dx.doi.org/10.18632/aging.103296

Ejemplares similares

CA125/MUC16 Is Dispensable for Mouse Development and Reproduction
por: Cheon, Dong-Joo, et al.
Publicado: (2009)

Polymorphisms of MUC16 (CA125) and MUC1 (CA15.3) in Relation to Ovarian Cancer Risk and Survival
por: Williams, Kristina A., et al.
Publicado: (2014)

Conflicting Views on the Molecular Structure of the Cancer Antigen CA125/MUC16
por: Bouanene, Houda, et al.
Publicado: (2010)

MUC16 (CA125): tumor biomarker to cancer therapy, a work in progress
por: Felder, Mildred, et al.
Publicado: (2014)

Knockdown of MUC16 (CA125) Enhances the Migration and Invasion of Hepatocellular Carcinoma Cells
por: Huang, Yao, et al.
Publicado: (2021)

Individual recombinant repeats of MUC16 display variable binding to CA125 antibodies
por: Wang, Chien-Wei, et al.
Publicado: (2023)

Expression of the Carboxy-Terminal Portion of MUC16/CA125 Induces Transformation and Tumor Invasion
por: Rao, Thapi D., et al.
Publicado: (2015)

Expression of MUC16/CA125 Is Associated with Impaired Survival in Patients with Surgically Resected Cholangiocarcinoma
por: Kinzler, Maximilian N., et al.
Publicado: (2022)

The Potential Role of MUC16 (CA125) Biomarker in Lung Cancer: A Magic Biomarker but with Adversity
por: Saad, Hebatallah M., et al.
Publicado: (2022)

Favorable outcome of patients with lung adenocarcinoma harboring POLE mutations and expressing high PD-L1
por: Liu, Liang, et al.
Publicado: (2018)

Favorable immune checkpoint inhibitor outcome of patients with melanoma and NSCLC harboring FAT1 mutations
por: Zhang, Wenjing, et al.
Publicado: (2022)

MUC16/CA125 in the Context of Modular Proteins with an Annotated Role in Adhesion-Related Processes: In Silico Analysis
por: Jankovic, Miroslava, et al.
Publicado: (2012)

MUC4, MUC16, and TTN genes mutation correlated with prognosis, and predicted tumor mutation burden and immunotherapy efficacy in gastric cancer and pan‐cancer
por: Yang, Yue, et al.
Publicado: (2020)

Favorable Immune Microenvironment in Patients with EGFR and MAPK Co-Mutations
por: Yang, Wang, et al.
Publicado: (2020)

Why MUC16 mutations lead to a better prognosis: A study based on The Cancer Genome Atlas gastric cancer cohort
por: Huang, Yu-Jie, et al.
Publicado: (2021)

Mesothelin Binding to CA125/MUC16 Promotes Pancreatic Cancer Cell Motility and Invasion via MMP-7 Activation
por: Chen, Shih-Hsun, et al.
Publicado: (2013)

PI3K pathway mutation predicts an activated immune microenvironment and better immunotherapeutic efficacy in head and neck squamous cell carcinoma
por: Wang, Libo, et al.
Publicado: (2023)

Mutation of MUC16 Is Associated With Tumor Mutational Burden and Lymph Node Metastasis in Patients With Gastric Cancer
por: Zhang, Fengxiang, et al.
Publicado: (2022)

HN125: A Novel Immunoadhesin Targeting MUC16 with Potential for Cancer Therapy
por: Xiang, Xinran, et al.
Publicado: (2011)

Association of MUC16 Mutation With Response to Immune Checkpoint Inhibitors in Solid Tumors
por: Zhang, Lei, et al.
Publicado: (2020)

Co-expression of mesothelin and CA125/MUC16 is a prognostic factor for breast cancer, especially in luminal-type breast cancer patients
por: Einama, Takahiro, et al.
Publicado: (2021)

Prognostic Value of MUC16 Mutation and Its Correlation with Immunity in Hepatocellular Carcinoma Patients
por: Liu, Bing, et al.
Publicado: (2022)

Comprehensive characterization of MUC16 mutations in lung adenocarcinoma for immunotherapies and prognosis: An observational study
por: Liu, Tingjun, et al.
Publicado: (2023)

MUC16 mucin (CA125) attenuates TRAIL-induced apoptosis by decreasing TRAIL receptor R2 expression and increasing c-FLIP expression
por: Matte, Isabelle, et al.
Publicado: (2014)

Characterization of the tumor marker muc16 (ca125) expressed by murine ovarian tumor cell lines and identification of a panel of cross-reactive monoclonal antibodies
por: Goodell, Cara AR, et al.
Publicado: (2009)

Downregulation of cell surface CA125/MUC16 induces epithelial-to-mesenchymal transition and restores EGFR signalling in NIH:OVCAR3 ovarian carcinoma cells
por: Comamala, M, et al.
Publicado: (2011)

Tumor necrosis factor-α and interferon-γ stimulate MUC16 (CA125) expression in breast, endometrial and ovarian cancers through NFκB
por: Morgado, Micaela, et al.
Publicado: (2016)

Targeting galectin-3 with a high-affinity antibody for inhibition of high-grade serous ovarian cancer and other MUC16/CA-125-expressing malignancies
por: Stasenko, Marina, et al.
Publicado: (2021)

MUC16 overexpression induced by gene mutations promotes lung cancer cell growth and invasion
por: Kanwal, Madiha, et al.
Publicado: (2018)

Bioinformatics Analysis Based on TCGA: MUC16 Mutation Correlates with Clinical Outcome in Gastric Cancer
por: Huang, Liang, et al.
Publicado: (2022)

Development and validation of a MUC16 mutation-associated immune prognostic model for lung adenocarcinoma
por: Liu, Honggang, et al.
Publicado: (2023)

Retracted: Prognostic Value of MUC16 Mutation and Its Correlation with Immunity in Hepatocellular Carcinoma Patients
por: and Alternative Medicine, Evidence-Based Complementary
Publicado: (2023)

Sequencing Analysis of MUC6 and MUC16 Gene Fragments in Patients with Oropharyngeal Squamous Cell Carcinoma Reveals Novel Mutations: A Preliminary Study
por: Gaździcka, Jadwiga, et al.
Publicado: (2023)

Prevalence of K-RAS mutations and CA125 tumor marker in patients with ovarian carcinoma
por: Bagherlou, Nazanin, et al.
Publicado: (2020)

NAV-001, a high-efficacy antibody-drug conjugate targeting mesothelin with improved delivery of a potent payload by counteracting MUC16/CA125 inhibitory effects
por: Nicolaides, Nicholas C., et al.
Publicado: (2023)

Radiotherapy remodels the tumor microenvironment for enhancing immunotherapeutic sensitivity
por: Liu, Senbo, et al.
Publicado: (2023)

Differential Expression of MUC12, MUC16, and MUC20 in Patients with Active and Remission Ulcerative Colitis
por: Yamamoto-Furusho, Jesús K., et al.
Publicado: (2015)

ERO1L promotes IL6/sIL6R signaling and regulates MUC16 expression to promote CA125 secretion and the metastasis of lung cancer cells
por: lei, Yuanyuan, et al.
Publicado: (2020)

CA125 Levels in BRCA mutation carriers – a retrospective single center cohort study
por: Gebhart, P, et al.
Publicado: (2023)

The favorable impact of PIK3CA mutations on survival: an analysis of 2587 patients with breast cancer
por: Dumont, Amaury G., et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_bfg5i5gjf7l6cea99irtvq0p58